Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

被引：22

作者：

Helbig, Grzegorz ^{[1
]}

Moskwa, Andrzej ^{[2
]}

Hus, Marek ^{[3
]}

Piszcz, Jaroslaw ^{[4
]}

Swiderska, Alina ^{[5
]}

Urbanowicz, Alina ^{[6
]}

Calbecka, Malgorzata ^{[7
]}

Seferynska, Ilona ^{[8
]}

Razny, Malgorzata ^{[9
]}

Rodzaj, Marek ^{[9
]}

Zuk, Ewa ^{[10
]}

Kyrcz-Krzemien, Slawomira ^{[1
]}

机构：

[1] Silesian Med Univ, Dept Haematol & Bone Marrow Transplantat, Katowice, Poland

[2] Prov Hosp, Dept Haematol, Gorzow Wielkopolski, Poland

[3] Med Univ, Dept Haematol, Lublin, Poland

[4] Med Univ, Dept Haematol, Bialystok, Poland

[5] Prov Hosp, Dept Haematol, Zielona Gora, Poland

[6] Prov Hosp, Dept Haematol, Suwalki, Poland

[7] Prov Hosp, Dept Haematol, Torun, Poland

[8] Med Univ, Inst Haematol & Transfus Med, Warsaw, Poland

[9] Rydygier Hosp, Dept Haematol & Internal Med, Krakow, Poland

[10] Prov Hosp, Dept Haematol, Szczecin, Poland

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2011年 / 67卷 / 04期

关键词：

MESYLATE; EFFICACY; THERAPY; FUSION;

D O I：

10.1007/s00280-011-1582-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：967 / 969

页数：3

共 11 条

[1] The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study [J].

Baccarani, Michele ;

Cilloni, Daniela ;

Rondoni, Michela ;

Ottaviani, Emanuela ;

Messa, Francesca ;

Merante, Serena ;

Tiribelli, Mario ;

Buccisano, Francesco ;

Testoni, Nicoletta ;

Gottardi, Enrico ;

de Vivo, Antonio ;

Giugliano, Emilia ;

Iacobucci, Ilaria ;

Paolini, Stefania ;

Soverini, Simona ;

Rosti, Gianantonio ;

Rancati, Francesca ;

Astolfi, Cinzia ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Martinelli, Giovanni .

HAEMATOLOGICA, 2007, 92 (09) :1173-1179

[2] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[3] The results of imatinib therapy for patients with primary eosinophilic disorders [J].

Helbig, G ;

Stella-Holowiecka, B ;

Grosicki, S ;

Bober, G ;

Krawczyk, M ;

Wojnar, J ;

Reiter, A ;

Hochhaus, A ;

Holowiecki, J .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (06) :535-536

[4] Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up [J].

Helbig, Grzegorz ;

Moskwa, Andrzej ;

Swiderska, Alina ;

Urbanowicz, Alina ;

Calbecka, Malgorzata ;

Gajkowska, Justyna ;

Zdziarska, Barbara ;

Brzezniakiewicz, Katarzyna ;

Pogrzeba, Joanna ;

Krzemien, Slawomira .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (01) :132-134

[5] Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia [J].

Jovanovic, Jelena V. ;

Score, Joannah ;

Waghorn, Katherine ;

Cilloni, Daniela ;

Gottardi, Enrico ;

Metzgeroth, Georgia ;

Erben, Philipp ;

Popp, Helena ;

Walz, Christoph ;

Hochhaus, Andreas ;

Roche-Lestienne, Catherine ;

Preudhomme, Claude ;

Solomon, Ellen ;

Apperley, Jane ;

Rondoni, Michela ;

Ottaviani, Emanuela ;

Martinelli, Giovanni ;

Brito-Babapulle, Finella ;

Saglio, Giuseppe ;

Hehlmann, Ruediger ;

Cross, Nicholas C. P. ;

Reiter, Andreas ;

Grimwade, David .

BLOOD, 2007, 109 (11) :4635-4640

[6] Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia:: implications for optimal dosing [J].

Klion, Amy D. ;

Robyn, Jamie ;

Maric, Irina ;

Fu, Weiming ;

Schmid, Laura ;

Lemery, Steven ;

Noel, Pierre ;

Law, Melissa A. ;

Hartsell, Marilyn ;

Talar-Williams, Cheryl ;

Fay, Michael P. ;

Dunbar, Cynthia E. ;

Nutman, Thomas B. .

BLOOD, 2007, 110 (10) :3552-3556

[7] FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib [J].

Lierman, E. ;

Michaux, L. ;

Beullens, E. ;

Pierre, P. ;

Marynen, P. ;

Cools, J. ;

Vandenberghe, P. .

LEUKEMIA, 2009, 23 (05) :845-851

[8] Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study [J].

Metzgeroth, Georgia ;

Walz, Christoph ;

Erben, Philipp ;

Popp, Helena ;

Schmitt-Graeff, Annette ;

Haferlach, Claudia ;

Fabarius, Alice ;

Schnittger, Susanne ;

Grimwade, David ;

Cross, Nicholas C. P. ;

Hehlmann, Ruediger ;

Hochhaus, Andreas ;

Reiter, Andreas .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (05) :707-715

[9]

Rondoni M, 2009, BLOOD, V114, P1498

[10] Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry [J].

Titier, Karine ;

Picard, Stephane ;

Ducint, Dominique ;

Teilhet, Emmanuelle ;

Moore, Nicholas ;

Berthaud, Patrice ;

Mahon, Francois-Xavier ;

Molimard, Mathieu .

THERAPEUTIC DRUG MONITORING, 2005, 27 (05) :634-640

← 1 2 →